AbbVie (ABBV) Change in Accured Expenses (2012 - 2026)

AbbVie (ABBV) has 15 years of Change in Accured Expenses data on file, last reported at -$1.6 billion in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.6 billion, down 129.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.0 million (up 106.02% YoY), and the FY2025 annual result was $951.0 million, up 437.29% from the prior year.
• Change in Accured Expenses slipped to -$1.6 billion in Q1 2026 per ABBV's latest filing, from -$598.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.5 billion in Q3 2023 and troughed at -$1.7 billion in Q2 2024.
• A 5-year average of $302.5 million and a median of $267.0 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses sank 363.89% in 2022, then soared 928.42% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $1.3 billion in 2022, then tumbled by 85.99% to $179.0 million in 2023, then soared by 596.65% to $1.2 billion in 2024, then sank by 147.96% to -$598.0 million in 2025, then sank by 166.56% to -$1.6 billion in 2026.
• Business Quant data shows ABBV's Change in Accured Expenses at -$1.6 billion in Q1 2026, -$598.0 million in Q4 2025, and $1.7 billion in Q3 2025.